Global Tumour Neoantigens Market Research Report 2024(Status and Outlook)
Report Overview
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
This report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Tumour Neoantigens Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Tumour Neoantigens market in any manner.
Global Tumour Neoantigens Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Achilles Therapeutics plc
Advaxis Immunotherapies
Genocea
Gradalis, Inc
Gritstone bio
Iovance Biotherapetics Inc
Medigene AG
BioNTech SE
Lilly
Scicomvisuals
Moderna, Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Sun Pharmaceutical Industries Ltd
Market Segmentation (by Type)
Common Neoantigens
Individualized Neoantigens
Market Segmentation (by Application)
T Cell Adoptive Therapy
DC Therapy
Therapeutic Vaccines
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Tumour Neoantigens Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
This report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Tumour Neoantigens Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Tumour Neoantigens market in any manner.
Global Tumour Neoantigens Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Achilles Therapeutics plc
Advaxis Immunotherapies
Genocea
Gradalis, Inc
Gritstone bio
Iovance Biotherapetics Inc
Medigene AG
BioNTech SE
Lilly
Scicomvisuals
Moderna, Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Sun Pharmaceutical Industries Ltd
Market Segmentation (by Type)
Common Neoantigens
Individualized Neoantigens
Market Segmentation (by Application)
T Cell Adoptive Therapy
DC Therapy
Therapeutic Vaccines
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Tumour Neoantigens Market
- Overview of the regional outlook of the Tumour Neoantigens Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Tumour Neoantigens Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Tumour Neoantigens
1.2 Key Market Segments
1.2.1 Tumour Neoantigens Segment by Type
1.2.2 Tumour Neoantigens Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TUMOUR NEOANTIGENS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Tumour Neoantigens Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Tumour Neoantigens Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TUMOUR NEOANTIGENS MARKET COMPETITIVE LANDSCAPE
3.1 Global Tumour Neoantigens Sales by Manufacturers (2019-2024)
3.2 Global Tumour Neoantigens Revenue Market Share by Manufacturers (2019-2024)
3.3 Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Tumour Neoantigens Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Tumour Neoantigens Sales Sites, Area Served, Product Type
3.6 Tumour Neoantigens Market Competitive Situation and Trends
3.6.1 Tumour Neoantigens Market Concentration Rate
3.6.2 Global 5 and 10 Largest Tumour Neoantigens Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 TUMOUR NEOANTIGENS INDUSTRY CHAIN ANALYSIS
4.1 Tumour Neoantigens Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TUMOUR NEOANTIGENS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Tumour Neoantigens Sales Market Share by Type (2019-2024)
6.3 Global Tumour Neoantigens Market Size Market Share by Type (2019-2024)
6.4 Global Tumour Neoantigens Price by Type (2019-2024)
7 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Tumour Neoantigens Market Sales by Application (2019-2024)
7.3 Global Tumour Neoantigens Market Size (M USD) by Application (2019-2024)
7.4 Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
8 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY REGION
8.1 Global Tumour Neoantigens Sales by Region
8.1.1 Global Tumour Neoantigens Sales by Region
8.1.2 Global Tumour Neoantigens Sales Market Share by Region
8.2 North America
8.2.1 North America Tumour Neoantigens Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Tumour Neoantigens Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Tumour Neoantigens Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Tumour Neoantigens Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Tumour Neoantigens Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Achilles Therapeutics plc
9.1.1 Achilles Therapeutics plc Tumour Neoantigens Basic Information
9.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Overview
9.1.3 Achilles Therapeutics plc Tumour Neoantigens Product Market Performance
9.1.4 Achilles Therapeutics plc Business Overview
9.1.5 Achilles Therapeutics plc Tumour Neoantigens SWOT Analysis
9.1.6 Achilles Therapeutics plc Recent Developments
9.2 Advaxis Immunotherapies
9.2.1 Advaxis Immunotherapies Tumour Neoantigens Basic Information
9.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Overview
9.2.3 Advaxis Immunotherapies Tumour Neoantigens Product Market Performance
9.2.4 Advaxis Immunotherapies Business Overview
9.2.5 Advaxis Immunotherapies Tumour Neoantigens SWOT Analysis
9.2.6 Advaxis Immunotherapies Recent Developments
9.3 Genocea
9.3.1 Genocea Tumour Neoantigens Basic Information
9.3.2 Genocea Tumour Neoantigens Product Overview
9.3.3 Genocea Tumour Neoantigens Product Market Performance
9.3.4 Genocea Tumour Neoantigens SWOT Analysis
9.3.5 Genocea Business Overview
9.3.6 Genocea Recent Developments
9.4 Gradalis, Inc
9.4.1 Gradalis, Inc Tumour Neoantigens Basic Information
9.4.2 Gradalis, Inc Tumour Neoantigens Product Overview
9.4.3 Gradalis, Inc Tumour Neoantigens Product Market Performance
9.4.4 Gradalis, Inc Business Overview
9.4.5 Gradalis, Inc Recent Developments
9.5 Gritstone bio
9.5.1 Gritstone bio Tumour Neoantigens Basic Information
9.5.2 Gritstone bio Tumour Neoantigens Product Overview
9.5.3 Gritstone bio Tumour Neoantigens Product Market Performance
9.5.4 Gritstone bio Business Overview
9.5.5 Gritstone bio Recent Developments
9.6 Iovance Biotherapetics Inc
9.6.1 Iovance Biotherapetics Inc Tumour Neoantigens Basic Information
9.6.2 Iovance Biotherapetics Inc Tumour Neoantigens Product Overview
9.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Product Market Performance
9.6.4 Iovance Biotherapetics Inc Business Overview
9.6.5 Iovance Biotherapetics Inc Recent Developments
9.7 Medigene AG
9.7.1 Medigene AG Tumour Neoantigens Basic Information
9.7.2 Medigene AG Tumour Neoantigens Product Overview
9.7.3 Medigene AG Tumour Neoantigens Product Market Performance
9.7.4 Medigene AG Business Overview
9.7.5 Medigene AG Recent Developments
9.8 BioNTech SE
9.8.1 BioNTech SE Tumour Neoantigens Basic Information
9.8.2 BioNTech SE Tumour Neoantigens Product Overview
9.8.3 BioNTech SE Tumour Neoantigens Product Market Performance
9.8.4 BioNTech SE Business Overview
9.8.5 BioNTech SE Recent Developments
9.9 Lilly
9.9.1 Lilly Tumour Neoantigens Basic Information
9.9.2 Lilly Tumour Neoantigens Product Overview
9.9.3 Lilly Tumour Neoantigens Product Market Performance
9.9.4 Lilly Business Overview
9.9.5 Lilly Recent Developments
9.10 Scicomvisuals
9.10.1 Scicomvisuals Tumour Neoantigens Basic Information
9.10.2 Scicomvisuals Tumour Neoantigens Product Overview
9.10.3 Scicomvisuals Tumour Neoantigens Product Market Performance
9.10.4 Scicomvisuals Business Overview
9.10.5 Scicomvisuals Recent Developments
9.11 Moderna, Inc
9.11.1 Moderna, Inc Tumour Neoantigens Basic Information
9.11.2 Moderna, Inc Tumour Neoantigens Product Overview
9.11.3 Moderna, Inc Tumour Neoantigens Product Market Performance
9.11.4 Moderna, Inc Business Overview
9.11.5 Moderna, Inc Recent Developments
9.12 F. Hoffmann-La Roche Ltd
9.12.1 F. Hoffmann-La Roche Ltd Tumour Neoantigens Basic Information
9.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Overview
9.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Market Performance
9.12.4 F. Hoffmann-La Roche Ltd Business Overview
9.12.5 F. Hoffmann-La Roche Ltd Recent Developments
9.13 Merck KGaA
9.13.1 Merck KGaA Tumour Neoantigens Basic Information
9.13.2 Merck KGaA Tumour Neoantigens Product Overview
9.13.3 Merck KGaA Tumour Neoantigens Product Market Performance
9.13.4 Merck KGaA Business Overview
9.13.5 Merck KGaA Recent Developments
9.14 Sun Pharmaceutical Industries Ltd
9.14.1 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Basic Information
9.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Overview
9.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Market Performance
9.14.4 Sun Pharmaceutical Industries Ltd Business Overview
9.14.5 Sun Pharmaceutical Industries Ltd Recent Developments
10 TUMOUR NEOANTIGENS MARKET FORECAST BY REGION
10.1 Global Tumour Neoantigens Market Size Forecast
10.2 Global Tumour Neoantigens Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Tumour Neoantigens Market Size Forecast by Country
10.2.3 Asia Pacific Tumour Neoantigens Market Size Forecast by Region
10.2.4 South America Tumour Neoantigens Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Tumour Neoantigens by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Tumour Neoantigens Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Tumour Neoantigens by Type (2025-2030)
11.1.2 Global Tumour Neoantigens Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Tumour Neoantigens by Type (2025-2030)
11.2 Global Tumour Neoantigens Market Forecast by Application (2025-2030)
11.2.1 Global Tumour Neoantigens Sales (Kilotons) Forecast by Application
11.2.2 Global Tumour Neoantigens Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Tumour Neoantigens
1.2 Key Market Segments
1.2.1 Tumour Neoantigens Segment by Type
1.2.2 Tumour Neoantigens Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 TUMOUR NEOANTIGENS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Tumour Neoantigens Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Tumour Neoantigens Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 TUMOUR NEOANTIGENS MARKET COMPETITIVE LANDSCAPE
3.1 Global Tumour Neoantigens Sales by Manufacturers (2019-2024)
3.2 Global Tumour Neoantigens Revenue Market Share by Manufacturers (2019-2024)
3.3 Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Tumour Neoantigens Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Tumour Neoantigens Sales Sites, Area Served, Product Type
3.6 Tumour Neoantigens Market Competitive Situation and Trends
3.6.1 Tumour Neoantigens Market Concentration Rate
3.6.2 Global 5 and 10 Largest Tumour Neoantigens Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 TUMOUR NEOANTIGENS INDUSTRY CHAIN ANALYSIS
4.1 Tumour Neoantigens Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF TUMOUR NEOANTIGENS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Tumour Neoantigens Sales Market Share by Type (2019-2024)
6.3 Global Tumour Neoantigens Market Size Market Share by Type (2019-2024)
6.4 Global Tumour Neoantigens Price by Type (2019-2024)
7 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Tumour Neoantigens Market Sales by Application (2019-2024)
7.3 Global Tumour Neoantigens Market Size (M USD) by Application (2019-2024)
7.4 Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
8 TUMOUR NEOANTIGENS MARKET SEGMENTATION BY REGION
8.1 Global Tumour Neoantigens Sales by Region
8.1.1 Global Tumour Neoantigens Sales by Region
8.1.2 Global Tumour Neoantigens Sales Market Share by Region
8.2 North America
8.2.1 North America Tumour Neoantigens Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Tumour Neoantigens Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Tumour Neoantigens Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Tumour Neoantigens Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Tumour Neoantigens Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Achilles Therapeutics plc
9.1.1 Achilles Therapeutics plc Tumour Neoantigens Basic Information
9.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Overview
9.1.3 Achilles Therapeutics plc Tumour Neoantigens Product Market Performance
9.1.4 Achilles Therapeutics plc Business Overview
9.1.5 Achilles Therapeutics plc Tumour Neoantigens SWOT Analysis
9.1.6 Achilles Therapeutics plc Recent Developments
9.2 Advaxis Immunotherapies
9.2.1 Advaxis Immunotherapies Tumour Neoantigens Basic Information
9.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Overview
9.2.3 Advaxis Immunotherapies Tumour Neoantigens Product Market Performance
9.2.4 Advaxis Immunotherapies Business Overview
9.2.5 Advaxis Immunotherapies Tumour Neoantigens SWOT Analysis
9.2.6 Advaxis Immunotherapies Recent Developments
9.3 Genocea
9.3.1 Genocea Tumour Neoantigens Basic Information
9.3.2 Genocea Tumour Neoantigens Product Overview
9.3.3 Genocea Tumour Neoantigens Product Market Performance
9.3.4 Genocea Tumour Neoantigens SWOT Analysis
9.3.5 Genocea Business Overview
9.3.6 Genocea Recent Developments
9.4 Gradalis, Inc
9.4.1 Gradalis, Inc Tumour Neoantigens Basic Information
9.4.2 Gradalis, Inc Tumour Neoantigens Product Overview
9.4.3 Gradalis, Inc Tumour Neoantigens Product Market Performance
9.4.4 Gradalis, Inc Business Overview
9.4.5 Gradalis, Inc Recent Developments
9.5 Gritstone bio
9.5.1 Gritstone bio Tumour Neoantigens Basic Information
9.5.2 Gritstone bio Tumour Neoantigens Product Overview
9.5.3 Gritstone bio Tumour Neoantigens Product Market Performance
9.5.4 Gritstone bio Business Overview
9.5.5 Gritstone bio Recent Developments
9.6 Iovance Biotherapetics Inc
9.6.1 Iovance Biotherapetics Inc Tumour Neoantigens Basic Information
9.6.2 Iovance Biotherapetics Inc Tumour Neoantigens Product Overview
9.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Product Market Performance
9.6.4 Iovance Biotherapetics Inc Business Overview
9.6.5 Iovance Biotherapetics Inc Recent Developments
9.7 Medigene AG
9.7.1 Medigene AG Tumour Neoantigens Basic Information
9.7.2 Medigene AG Tumour Neoantigens Product Overview
9.7.3 Medigene AG Tumour Neoantigens Product Market Performance
9.7.4 Medigene AG Business Overview
9.7.5 Medigene AG Recent Developments
9.8 BioNTech SE
9.8.1 BioNTech SE Tumour Neoantigens Basic Information
9.8.2 BioNTech SE Tumour Neoantigens Product Overview
9.8.3 BioNTech SE Tumour Neoantigens Product Market Performance
9.8.4 BioNTech SE Business Overview
9.8.5 BioNTech SE Recent Developments
9.9 Lilly
9.9.1 Lilly Tumour Neoantigens Basic Information
9.9.2 Lilly Tumour Neoantigens Product Overview
9.9.3 Lilly Tumour Neoantigens Product Market Performance
9.9.4 Lilly Business Overview
9.9.5 Lilly Recent Developments
9.10 Scicomvisuals
9.10.1 Scicomvisuals Tumour Neoantigens Basic Information
9.10.2 Scicomvisuals Tumour Neoantigens Product Overview
9.10.3 Scicomvisuals Tumour Neoantigens Product Market Performance
9.10.4 Scicomvisuals Business Overview
9.10.5 Scicomvisuals Recent Developments
9.11 Moderna, Inc
9.11.1 Moderna, Inc Tumour Neoantigens Basic Information
9.11.2 Moderna, Inc Tumour Neoantigens Product Overview
9.11.3 Moderna, Inc Tumour Neoantigens Product Market Performance
9.11.4 Moderna, Inc Business Overview
9.11.5 Moderna, Inc Recent Developments
9.12 F. Hoffmann-La Roche Ltd
9.12.1 F. Hoffmann-La Roche Ltd Tumour Neoantigens Basic Information
9.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Overview
9.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Market Performance
9.12.4 F. Hoffmann-La Roche Ltd Business Overview
9.12.5 F. Hoffmann-La Roche Ltd Recent Developments
9.13 Merck KGaA
9.13.1 Merck KGaA Tumour Neoantigens Basic Information
9.13.2 Merck KGaA Tumour Neoantigens Product Overview
9.13.3 Merck KGaA Tumour Neoantigens Product Market Performance
9.13.4 Merck KGaA Business Overview
9.13.5 Merck KGaA Recent Developments
9.14 Sun Pharmaceutical Industries Ltd
9.14.1 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Basic Information
9.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Overview
9.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Market Performance
9.14.4 Sun Pharmaceutical Industries Ltd Business Overview
9.14.5 Sun Pharmaceutical Industries Ltd Recent Developments
10 TUMOUR NEOANTIGENS MARKET FORECAST BY REGION
10.1 Global Tumour Neoantigens Market Size Forecast
10.2 Global Tumour Neoantigens Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Tumour Neoantigens Market Size Forecast by Country
10.2.3 Asia Pacific Tumour Neoantigens Market Size Forecast by Region
10.2.4 South America Tumour Neoantigens Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Tumour Neoantigens by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Tumour Neoantigens Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Tumour Neoantigens by Type (2025-2030)
11.1.2 Global Tumour Neoantigens Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Tumour Neoantigens by Type (2025-2030)
11.2 Global Tumour Neoantigens Market Forecast by Application (2025-2030)
11.2.1 Global Tumour Neoantigens Sales (Kilotons) Forecast by Application
11.2.2 Global Tumour Neoantigens Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Tumour Neoantigens Market Size Comparison by Region (M USD)
Table 5. Global Tumour Neoantigens Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Tumour Neoantigens Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Tumour Neoantigens Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Tumour Neoantigens Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour Neoantigens as of 2022)
Table 10. Global Market Tumour Neoantigens Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Tumour Neoantigens Sales Sites and Area Served
Table 12. Manufacturers Tumour Neoantigens Product Type
Table 13. Global Tumour Neoantigens Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Tumour Neoantigens
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Tumour Neoantigens Market Challenges
Table 22. Global Tumour Neoantigens Sales by Type (Kilotons)
Table 23. Global Tumour Neoantigens Market Size by Type (M USD)
Table 24. Global Tumour Neoantigens Sales (Kilotons) by Type (2019-2024)
Table 25. Global Tumour Neoantigens Sales Market Share by Type (2019-2024)
Table 26. Global Tumour Neoantigens Market Size (M USD) by Type (2019-2024)
Table 27. Global Tumour Neoantigens Market Size Share by Type (2019-2024)
Table 28. Global Tumour Neoantigens Price (USD/Ton) by Type (2019-2024)
Table 29. Global Tumour Neoantigens Sales (Kilotons) by Application
Table 30. Global Tumour Neoantigens Market Size by Application
Table 31. Global Tumour Neoantigens Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Tumour Neoantigens Sales Market Share by Application (2019-2024)
Table 33. Global Tumour Neoantigens Sales by Application (2019-2024) & (M USD)
Table 34. Global Tumour Neoantigens Market Share by Application (2019-2024)
Table 35. Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
Table 36. Global Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Tumour Neoantigens Sales Market Share by Region (2019-2024)
Table 38. North America Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 43. Achilles Therapeutics plc Tumour Neoantigens Basic Information
Table 44. Achilles Therapeutics plc Tumour Neoantigens Product Overview
Table 45. Achilles Therapeutics plc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Achilles Therapeutics plc Business Overview
Table 47. Achilles Therapeutics plc Tumour Neoantigens SWOT Analysis
Table 48. Achilles Therapeutics plc Recent Developments
Table 49. Advaxis Immunotherapies Tumour Neoantigens Basic Information
Table 50. Advaxis Immunotherapies Tumour Neoantigens Product Overview
Table 51. Advaxis Immunotherapies Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Advaxis Immunotherapies Business Overview
Table 53. Advaxis Immunotherapies Tumour Neoantigens SWOT Analysis
Table 54. Advaxis Immunotherapies Recent Developments
Table 55. Genocea Tumour Neoantigens Basic Information
Table 56. Genocea Tumour Neoantigens Product Overview
Table 57. Genocea Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Genocea Tumour Neoantigens SWOT Analysis
Table 59. Genocea Business Overview
Table 60. Genocea Recent Developments
Table 61. Gradalis, Inc Tumour Neoantigens Basic Information
Table 62. Gradalis, Inc Tumour Neoantigens Product Overview
Table 63. Gradalis, Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Gradalis, Inc Business Overview
Table 65. Gradalis, Inc Recent Developments
Table 66. Gritstone bio Tumour Neoantigens Basic Information
Table 67. Gritstone bio Tumour Neoantigens Product Overview
Table 68. Gritstone bio Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Gritstone bio Business Overview
Table 70. Gritstone bio Recent Developments
Table 71. Iovance Biotherapetics Inc Tumour Neoantigens Basic Information
Table 72. Iovance Biotherapetics Inc Tumour Neoantigens Product Overview
Table 73. Iovance Biotherapetics Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Iovance Biotherapetics Inc Business Overview
Table 75. Iovance Biotherapetics Inc Recent Developments
Table 76. Medigene AG Tumour Neoantigens Basic Information
Table 77. Medigene AG Tumour Neoantigens Product Overview
Table 78. Medigene AG Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Medigene AG Business Overview
Table 80. Medigene AG Recent Developments
Table 81. BioNTech SE Tumour Neoantigens Basic Information
Table 82. BioNTech SE Tumour Neoantigens Product Overview
Table 83. BioNTech SE Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. BioNTech SE Business Overview
Table 85. BioNTech SE Recent Developments
Table 86. Lilly Tumour Neoantigens Basic Information
Table 87. Lilly Tumour Neoantigens Product Overview
Table 88. Lilly Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Lilly Business Overview
Table 90. Lilly Recent Developments
Table 91. Scicomvisuals Tumour Neoantigens Basic Information
Table 92. Scicomvisuals Tumour Neoantigens Product Overview
Table 93. Scicomvisuals Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Scicomvisuals Business Overview
Table 95. Scicomvisuals Recent Developments
Table 96. Moderna, Inc Tumour Neoantigens Basic Information
Table 97. Moderna, Inc Tumour Neoantigens Product Overview
Table 98. Moderna, Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Moderna, Inc Business Overview
Table 100. Moderna, Inc Recent Developments
Table 101. F. Hoffmann-La Roche Ltd Tumour Neoantigens Basic Information
Table 102. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Overview
Table 103. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. F. Hoffmann-La Roche Ltd Business Overview
Table 105. F. Hoffmann-La Roche Ltd Recent Developments
Table 106. Merck KGaA Tumour Neoantigens Basic Information
Table 107. Merck KGaA Tumour Neoantigens Product Overview
Table 108. Merck KGaA Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Merck KGaA Business Overview
Table 110. Merck KGaA Recent Developments
Table 111. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Basic Information
Table 112. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Overview
Table 113. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Sun Pharmaceutical Industries Ltd Business Overview
Table 115. Sun Pharmaceutical Industries Ltd Recent Developments
Table 116. Global Tumour Neoantigens Sales Forecast by Region (2025-2030) & (Kilotons)
Table 117. Global Tumour Neoantigens Market Size Forecast by Region (2025-2030) & (M USD)
Table 118. North America Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 119. North America Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 120. Europe Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 121. Europe Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Asia Pacific Tumour Neoantigens Sales Forecast by Region (2025-2030) & (Kilotons)
Table 123. Asia Pacific Tumour Neoantigens Market Size Forecast by Region (2025-2030) & (M USD)
Table 124. South America Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 125. South America Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 126. Middle East and Africa Tumour Neoantigens Consumption Forecast by Country (2025-2030) & (Units)
Table 127. Middle East and Africa Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 128. Global Tumour Neoantigens Sales Forecast by Type (2025-2030) & (Kilotons)
Table 129. Global Tumour Neoantigens Market Size Forecast by Type (2025-2030) & (M USD)
Table 130. Global Tumour Neoantigens Price Forecast by Type (2025-2030) & (USD/Ton)
Table 131. Global Tumour Neoantigens Sales (Kilotons) Forecast by Application (2025-2030)
Table 132. Global Tumour Neoantigens Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Tumour Neoantigens Market Size Comparison by Region (M USD)
Table 5. Global Tumour Neoantigens Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Tumour Neoantigens Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Tumour Neoantigens Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Tumour Neoantigens Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumour Neoantigens as of 2022)
Table 10. Global Market Tumour Neoantigens Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Tumour Neoantigens Sales Sites and Area Served
Table 12. Manufacturers Tumour Neoantigens Product Type
Table 13. Global Tumour Neoantigens Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Tumour Neoantigens
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Tumour Neoantigens Market Challenges
Table 22. Global Tumour Neoantigens Sales by Type (Kilotons)
Table 23. Global Tumour Neoantigens Market Size by Type (M USD)
Table 24. Global Tumour Neoantigens Sales (Kilotons) by Type (2019-2024)
Table 25. Global Tumour Neoantigens Sales Market Share by Type (2019-2024)
Table 26. Global Tumour Neoantigens Market Size (M USD) by Type (2019-2024)
Table 27. Global Tumour Neoantigens Market Size Share by Type (2019-2024)
Table 28. Global Tumour Neoantigens Price (USD/Ton) by Type (2019-2024)
Table 29. Global Tumour Neoantigens Sales (Kilotons) by Application
Table 30. Global Tumour Neoantigens Market Size by Application
Table 31. Global Tumour Neoantigens Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Tumour Neoantigens Sales Market Share by Application (2019-2024)
Table 33. Global Tumour Neoantigens Sales by Application (2019-2024) & (M USD)
Table 34. Global Tumour Neoantigens Market Share by Application (2019-2024)
Table 35. Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
Table 36. Global Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Tumour Neoantigens Sales Market Share by Region (2019-2024)
Table 38. North America Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Tumour Neoantigens Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Tumour Neoantigens Sales by Region (2019-2024) & (Kilotons)
Table 43. Achilles Therapeutics plc Tumour Neoantigens Basic Information
Table 44. Achilles Therapeutics plc Tumour Neoantigens Product Overview
Table 45. Achilles Therapeutics plc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Achilles Therapeutics plc Business Overview
Table 47. Achilles Therapeutics plc Tumour Neoantigens SWOT Analysis
Table 48. Achilles Therapeutics plc Recent Developments
Table 49. Advaxis Immunotherapies Tumour Neoantigens Basic Information
Table 50. Advaxis Immunotherapies Tumour Neoantigens Product Overview
Table 51. Advaxis Immunotherapies Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Advaxis Immunotherapies Business Overview
Table 53. Advaxis Immunotherapies Tumour Neoantigens SWOT Analysis
Table 54. Advaxis Immunotherapies Recent Developments
Table 55. Genocea Tumour Neoantigens Basic Information
Table 56. Genocea Tumour Neoantigens Product Overview
Table 57. Genocea Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Genocea Tumour Neoantigens SWOT Analysis
Table 59. Genocea Business Overview
Table 60. Genocea Recent Developments
Table 61. Gradalis, Inc Tumour Neoantigens Basic Information
Table 62. Gradalis, Inc Tumour Neoantigens Product Overview
Table 63. Gradalis, Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Gradalis, Inc Business Overview
Table 65. Gradalis, Inc Recent Developments
Table 66. Gritstone bio Tumour Neoantigens Basic Information
Table 67. Gritstone bio Tumour Neoantigens Product Overview
Table 68. Gritstone bio Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. Gritstone bio Business Overview
Table 70. Gritstone bio Recent Developments
Table 71. Iovance Biotherapetics Inc Tumour Neoantigens Basic Information
Table 72. Iovance Biotherapetics Inc Tumour Neoantigens Product Overview
Table 73. Iovance Biotherapetics Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Iovance Biotherapetics Inc Business Overview
Table 75. Iovance Biotherapetics Inc Recent Developments
Table 76. Medigene AG Tumour Neoantigens Basic Information
Table 77. Medigene AG Tumour Neoantigens Product Overview
Table 78. Medigene AG Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Medigene AG Business Overview
Table 80. Medigene AG Recent Developments
Table 81. BioNTech SE Tumour Neoantigens Basic Information
Table 82. BioNTech SE Tumour Neoantigens Product Overview
Table 83. BioNTech SE Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. BioNTech SE Business Overview
Table 85. BioNTech SE Recent Developments
Table 86. Lilly Tumour Neoantigens Basic Information
Table 87. Lilly Tumour Neoantigens Product Overview
Table 88. Lilly Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Lilly Business Overview
Table 90. Lilly Recent Developments
Table 91. Scicomvisuals Tumour Neoantigens Basic Information
Table 92. Scicomvisuals Tumour Neoantigens Product Overview
Table 93. Scicomvisuals Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Scicomvisuals Business Overview
Table 95. Scicomvisuals Recent Developments
Table 96. Moderna, Inc Tumour Neoantigens Basic Information
Table 97. Moderna, Inc Tumour Neoantigens Product Overview
Table 98. Moderna, Inc Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 99. Moderna, Inc Business Overview
Table 100. Moderna, Inc Recent Developments
Table 101. F. Hoffmann-La Roche Ltd Tumour Neoantigens Basic Information
Table 102. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Overview
Table 103. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 104. F. Hoffmann-La Roche Ltd Business Overview
Table 105. F. Hoffmann-La Roche Ltd Recent Developments
Table 106. Merck KGaA Tumour Neoantigens Basic Information
Table 107. Merck KGaA Tumour Neoantigens Product Overview
Table 108. Merck KGaA Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 109. Merck KGaA Business Overview
Table 110. Merck KGaA Recent Developments
Table 111. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Basic Information
Table 112. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Overview
Table 113. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 114. Sun Pharmaceutical Industries Ltd Business Overview
Table 115. Sun Pharmaceutical Industries Ltd Recent Developments
Table 116. Global Tumour Neoantigens Sales Forecast by Region (2025-2030) & (Kilotons)
Table 117. Global Tumour Neoantigens Market Size Forecast by Region (2025-2030) & (M USD)
Table 118. North America Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 119. North America Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 120. Europe Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 121. Europe Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Asia Pacific Tumour Neoantigens Sales Forecast by Region (2025-2030) & (Kilotons)
Table 123. Asia Pacific Tumour Neoantigens Market Size Forecast by Region (2025-2030) & (M USD)
Table 124. South America Tumour Neoantigens Sales Forecast by Country (2025-2030) & (Kilotons)
Table 125. South America Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 126. Middle East and Africa Tumour Neoantigens Consumption Forecast by Country (2025-2030) & (Units)
Table 127. Middle East and Africa Tumour Neoantigens Market Size Forecast by Country (2025-2030) & (M USD)
Table 128. Global Tumour Neoantigens Sales Forecast by Type (2025-2030) & (Kilotons)
Table 129. Global Tumour Neoantigens Market Size Forecast by Type (2025-2030) & (M USD)
Table 130. Global Tumour Neoantigens Price Forecast by Type (2025-2030) & (USD/Ton)
Table 131. Global Tumour Neoantigens Sales (Kilotons) Forecast by Application (2025-2030)
Table 132. Global Tumour Neoantigens Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Tumour Neoantigens
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Tumour Neoantigens Market Size (M USD), 2019-2030
Figure 5. Global Tumour Neoantigens Market Size (M USD) (2019-2030)
Figure 6. Global Tumour Neoantigens Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Tumour Neoantigens Market Size by Country (M USD)
Figure 11. Tumour Neoantigens Sales Share by Manufacturers in 2023
Figure 12. Global Tumour Neoantigens Revenue Share by Manufacturers in 2023
Figure 13. Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Tumour Neoantigens Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Tumour Neoantigens Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Tumour Neoantigens Market Share by Type
Figure 18. Sales Market Share of Tumour Neoantigens by Type (2019-2024)
Figure 19. Sales Market Share of Tumour Neoantigens by Type in 2023
Figure 20. Market Size Share of Tumour Neoantigens by Type (2019-2024)
Figure 21. Market Size Market Share of Tumour Neoantigens by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Tumour Neoantigens Market Share by Application
Figure 24. Global Tumour Neoantigens Sales Market Share by Application (2019-2024)
Figure 25. Global Tumour Neoantigens Sales Market Share by Application in 2023
Figure 26. Global Tumour Neoantigens Market Share by Application (2019-2024)
Figure 27. Global Tumour Neoantigens Market Share by Application in 2023
Figure 28. Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
Figure 29. Global Tumour Neoantigens Sales Market Share by Region (2019-2024)
Figure 30. North America Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Tumour Neoantigens Sales Market Share by Country in 2023
Figure 32. U.S. Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Tumour Neoantigens Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Tumour Neoantigens Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Tumour Neoantigens Sales Market Share by Country in 2023
Figure 37. Germany Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Tumour Neoantigens Sales Market Share by Region in 2023
Figure 44. China Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 50. South America Tumour Neoantigens Sales Market Share by Country in 2023
Figure 51. Brazil Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Tumour Neoantigens Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Tumour Neoantigens Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Tumour Neoantigens Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Tumour Neoantigens Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Tumour Neoantigens Market Share Forecast by Type (2025-2030)
Figure 65. Global Tumour Neoantigens Sales Forecast by Application (2025-2030)
Figure 66. Global Tumour Neoantigens Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Tumour Neoantigens
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Tumour Neoantigens Market Size (M USD), 2019-2030
Figure 5. Global Tumour Neoantigens Market Size (M USD) (2019-2030)
Figure 6. Global Tumour Neoantigens Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Tumour Neoantigens Market Size by Country (M USD)
Figure 11. Tumour Neoantigens Sales Share by Manufacturers in 2023
Figure 12. Global Tumour Neoantigens Revenue Share by Manufacturers in 2023
Figure 13. Tumour Neoantigens Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Tumour Neoantigens Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Tumour Neoantigens Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Tumour Neoantigens Market Share by Type
Figure 18. Sales Market Share of Tumour Neoantigens by Type (2019-2024)
Figure 19. Sales Market Share of Tumour Neoantigens by Type in 2023
Figure 20. Market Size Share of Tumour Neoantigens by Type (2019-2024)
Figure 21. Market Size Market Share of Tumour Neoantigens by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Tumour Neoantigens Market Share by Application
Figure 24. Global Tumour Neoantigens Sales Market Share by Application (2019-2024)
Figure 25. Global Tumour Neoantigens Sales Market Share by Application in 2023
Figure 26. Global Tumour Neoantigens Market Share by Application (2019-2024)
Figure 27. Global Tumour Neoantigens Market Share by Application in 2023
Figure 28. Global Tumour Neoantigens Sales Growth Rate by Application (2019-2024)
Figure 29. Global Tumour Neoantigens Sales Market Share by Region (2019-2024)
Figure 30. North America Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Tumour Neoantigens Sales Market Share by Country in 2023
Figure 32. U.S. Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Tumour Neoantigens Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Tumour Neoantigens Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Tumour Neoantigens Sales Market Share by Country in 2023
Figure 37. Germany Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Tumour Neoantigens Sales Market Share by Region in 2023
Figure 44. China Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 50. South America Tumour Neoantigens Sales Market Share by Country in 2023
Figure 51. Brazil Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Tumour Neoantigens Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Tumour Neoantigens Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Tumour Neoantigens Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Tumour Neoantigens Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Tumour Neoantigens Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Tumour Neoantigens Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Tumour Neoantigens Market Share Forecast by Type (2025-2030)
Figure 65. Global Tumour Neoantigens Sales Forecast by Application (2025-2030)
Figure 66. Global Tumour Neoantigens Market Share Forecast by Application (2025-2030)
